GlassScriptPhysician profile
Heidi M Marcozzi
NPI 1316319973
$1,694.00
in general payments reported to CMS, 2019-2025
28 companies · $513 in 2025
The $513 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.17 · 2022: $152 · 2023: $279 · 2024: $694 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $257.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $231.45 | 2021-2025 | |
| Novo Nordisk INC | $216.83 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $127.48 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $104.27 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $84.99 | 2023-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $79.82 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $67.82 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $62.57 | 2024-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $52.10 | 2023-2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $40.90 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $36.43 | 2023-2024 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $35.59 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.01 | 2023-2024 | Jardiance |
| Hologic Sales and Service, LLC | $25.72 | 2024 | Aptima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.81 | 2023 | Sunosi |
| Esperion Therapeutics, INC. | $20.85 | 2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $19.83 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $19.57 | 2023 | Rexulti |
| Becton, Dickinson and Company | $19.16 | 2024 | Bd Max System, Bd Max Instrument |
| Seqirus USA INC | $18.68 | 2024 | Flucelvax, Fluad |
| Dynavax Technologies Corporation | $18.64 | 2023 | Heplisav-B |
| Tms Neurohealth Centers INC. | $18.57 | 2025 | Tms Neurohealth Centers INC. |
| Dexcom, INC. | $18.38 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $16.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.11 | 2024 | |
| Inspire Medical Systems, INC. | $13.99 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Marcozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.